[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Beijing Chest Hospital, Capital Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":87},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100639495","a-15-year-cohort-study-on-risk-factors-of-mortality-in-patients-with-intestinal-tuberculosis-100639495",false,"NCT07575061","A 15-year Cohort Study on Risk Factors of Mortality in Patients With Intestinal Tuberculosis","A 15-Year Cohort Study to Analyze Risk Factors for Mortality in Patients With Intestinal Tuberculosis","Inclusion Criteria:\n\n1. Aged ≥18 years old (no upper age limit) at the time of intestinal tuberculosis diagnosis;\n2. Diagnosed with intestinal tuberculosis in accordance with clinical diagnostic criteria (combined with clinical manifestations, laboratory examinations, imaging findings, and\u002For pathological results);\n3. For the Retrospective Intestinal Tuberculosis Cohort: diagnosed between January 2011 and December 2025, with complete medical records and follow-up data (including mortality status);\n4. For the Prospective Intestinal Tuberculosis Cohort: newly diagnosed, able to cooperate with regular follow-up, and sign the informed consent form (if applicable);\n5. No severe cognitive impairment or mental illness that affects the collection of clinical data and follow-up.\n\nExclusion Criteria:\n\n1. Patients with incomplete diagnosis of intestinal tuberculosis (no clear clinical, laboratory, imaging or pathological evidence to confirm the diagnosis);\n2. Patients with concurrent severe extrapulmonary tuberculosis (such as tuberculous meningitis, miliary tuberculosis) that may independently affect mortality outcomes;\n3. For the Retrospective Intestinal Tuberculosis Cohort: patients with incomplete medical records or missing key follow-up data (especially mortality status and related risk factor information);\n4. For the Prospective Intestinal Tuberculosis Cohort: patients who refuse to sign the informed consent form (if applicable), cannot cooperate with regular follow-up, or are lost to follow-up during the study period;\n5. Patients with severe comorbidities that may lead to rapid death (such as advanced malignant tumors, severe heart failure, end-stage liver\u002Fkidney disease) within the study period, which may interfere with the analysis of mortality risk factors related to intestinal tuberculosis;\n6. Patients with cognitive impairment, mental illness or other conditions that cannot provide effective clinical information or cooperate with the study.",true,"ALL","18 Years","100 Years",{"count":21,"type":22},500,"ESTIMATED","OBSERVATIONAL","This study adopts a combined design of retrospective cohort study followed by prospective observational study, which is conducted at Beijing Chest Hospital. The study first collects and analyzes the data of intestinal tuberculosis patients diagnosed and followed up in the hospital from 2011-1 to 2025-12 (a 15-year retrospective period) as the retrospective cohort, aiming to initially identify the risk factors associated with mortality in patients with intestinal tuberculosis. On the basis of the retrospective analysis results, the study will further carry out a prospective observational study, continuously enroll new intestinal tuberculosis patients, follow up their clinical status, treatment response and mortality outcomes for a certain period, and verify and supplement the risk factors identified in the retrospective stage. Clinical data, including demographic characteristics, clinical manifestations, laboratory test results, treatment regimens, and follow-up outcomes (mortality status), will be collected and sorted out in both stages. Univariate and multivariate statistical analyses will be used to screen and verify potential risk factors (such as age, disease severity, comorbidities, and treatment compliance) that affect the mortality of patients with intestinal tuberculosis. The results of this study are expected to provide scientific evidence for optimizing the clinical management, risk assessment, and prognostic improvement of patients with intestinal tuberculosis, and further guide the formulation of targeted prevention and treatment strategies.",[26],"Intestinal Tuberculosis","RECRUITING","2026-05-03",{"date":30,"type":31},"2026-05-08","ACTUAL",{"date":33,"type":31},"2026-01-01",{"date":35,"type":22},"2036-12-01",{"name":37,"class":38},"Beijing Chest Hospital, Capital Medical University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":39},"100552017","phase-2-adebrelimab-plus-chemo-and-recaticimab-in-perioperative-treatment-of-resectable-nsclc-100552017","NCT06467617","Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC","A Phase II Clinical Study of Adabrelimab Combined With Carboplatin, Albumin-bound Paclitaxel, and Recaticimab in Perioperative Treatment of Resectable NSCLC","Inclusion Criteria:\n\n1. 18-75 years old, male and female;\n2. ECOG PS 0-1;\n3. Histologically or cytologically confirmed operable stage II-III NSCLC (stages II, IIIA, and T3N2M0 IIIB) according to the UICC and AJCC 8th edition TNM staging system. Non-massive metastases (short diameter ≤2cm Lymph nodes) with expected complete resectable N2;\n4. With a measurable lesions (per RECIST 1.1 standard, tumor lesions on CT scan length to diameter 10 mm, or lymph node lesions on CT scans short diameter 15 mm or higher);\n5. Anti-tumor treatment (radiotherapy, chemotherapy, surgery, and targeted therapy) naive enrollment;\n6. Enough of lung function to go through R0 resection with a purpose of cure;\n7. Normal main organs function, should meet the following criteria: (1) the blood routine examination shall meet within 14 days (without blood transfusion, hematopoietic factor not used and unused drugs to correct) a. ANC≥1.8 x 109 \u002F L; B. Hb≥100 g\u002FL; C. PLT ≥ 125×109\u002FL; (2) Biochemical examination must meet the following criteria: a. TBIL ≤ 1.5ULN; B. ALT、AST≤2.5 ULN; Serum creatinine sCr≤1.5ULN, endogenous creatinine clearance≥50ml\u002Fmin (Cockcroft-Gault formula)\n\nExclusion criteria\n\n1. Known EGFR or ALK mutation;\n2. T4 tumors invading the heart, great vessels, trachea, recurrent laryngeal nerve, esophagus, vertebral body, tracheal carina, Upper sulcus lung cancer;\n3. Use of immunosuppressive drugs within 4 weeks before the first dose of study drug, excluding nasal spray and inhaled corticosteroids or physiological doses of systemic steroids (i.e., ≤10 mg\u002Fday of prednisolone or other corticosteroids at physiological doses of equivalent drugs, with discontinuation of the drug for ≥1 week);\n4. Received immunoregulatory effects of herbal medicine or Immune regulating effect of drugs (including thymosin, interferon, interleukin, except for local control Pleural effusion use) within 4 weeks before the first use of the study drug;\n5. Malignant tumors other than NSCLC occurred within 5 years before enrollment.\n6. Administered Live attenuated vaccine ≤ 4 weeks before the first dose or will be planned for the duration of the study；\n7. Current are participating in clinical research and treatment of intrusive, or within 4 weeks before the first delivery received study drugs or other treatments; Not fully recovered from any intervention-related toxicity and\u002For complications before the first dose (i.e., ≤ grade 1 or baseline, excluding fatigue or alopecia)；\n8. Severe infection (e.g., requiring intravenous antibiotics, antifungal or antiviral drugs) within 4 weeks before the first dose, or unexplained fever during screening\u002Fbefore the first dose. 38.5°C；\n9. Have or suspected a history of pneumonia\u002Finterstitial lung disease or any lung disease that would interfere with pulmonary function testing;\n10. With any active history of autoimmune disease or autoimmune diseases; Patients with complete remission of childhood asthma without any intervention in adulthood or with vitiligo were eligible;\n11. With congenital or acquired immune function defects, such as human immunodeficiency virus (HIV) infection, active hepatitis B, hepatitis C, hepatitis B and hepatitis C infection together and alcoholic liver cirrhosis patients;\n12. Patients with grade II or higher myocardial ischemia or myocardial infarction, poorly controlled arrhythmia (including QTc interval ≥450ms in men and ≥470ms in women). According to NYHA standard, grade III \\~ Ⅳ cardiac insufficiency, or heart colour to exceed examination prompt left ventricular ejection fraction (LVEF) \\\u003C 50% into the group of the first six months happened myocardial infarction, heart failure, New York heart association class II or above has not been control angina pectoris, out of control of severe ventricular arrhythmia, with clinical significance of cardiac disease, Or abnormal electrocardiogram (ecg) indicate that acute ischemia or active conduction system;\n13. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) more than 2 times the upper limit of normal value, or total bilirubin more than 1.5 times the upper limit of normal value (ULN); Creatine kinase (CK) was more than 3 times the upper limit of normal; There were major hemorrhagic events or arteriovenous thrombotic events\n14. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n15. Known allergy, hypersensitivity, or intolerance to the study drug or its excipients;\n16. Any condition considered by the investigator to be present that could harm the subject or cause the subject to be unable to meet or perform the requirements of the study.","75 Years",{"count":49,"type":22},35,"INTERVENTIONAL",[52],"PHASE2","Current studies confirmed that the immune perioperative treatment with combination chemotherapy curative effect and safety of resectable NSCLC, but its short-term curative effect and long-term survival benefit remains to be further improved to explore the new way of immune combination therapy.\n\nExperimental study showed that the inhibition of PCSK9 could significantly increase in tumor cells of the immune response in mice, inhibit the PCSK9 enhanced anti-tumor immune response of mice can be further coordinate with immune checkpoint therapy, forming a lasting anti-tumor immune effect.\n\nThere are no reports on the peri-operative treatment of immune combined with chemotherapy and PCSK-9 inhibitors in patients with resectable NSCLC.\n\nBased on the above, the aim of this study is to explore the efficacy and safety of Adebrelimab combined with recaticimab and chemotherapy in the perioperative treatment of patients with resectable NSCLC.",[55],"Non Small Cell Lung Cancer","2024-12-11",{"date":58,"type":31},"2024-12-16",{"date":60,"type":31},"2024-08-14",{"date":62,"type":22},"2027-03-01",{"name":37,"class":38},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":70,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":47,"enrollmentInfo":72,"targetDuration":4,"studyType":50,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":4},"100544916","phase-2-pd-l1pd-1-inhibitors-plus-chemotherapy-versus-chemotherapy-alone-for-the-neoadjuvant-treatment-of-limited-stage-sclc-100544916","NCT06375109","PD-L1\u002FPD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage SCLC","PD-L1\u002FPD-1 Inhibitors Plus Chemotherapy Versus Chemotherapy Alone for the Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer: an Open-label, Non-randomized Controlled, Phase II, Single-center Study","NeoSCLC-001","Inclusion Criteria:\n\n1. Patients voluntarily participated in this study, signed an informed consent form, and demonstrated good compliance.\n2. They were histologically or cytologically confirmed with limited-stage small-cell lung cancer (TNM stage; T1-3N0-2M0).\n3. The age range was 18 to 75 years, with no gender restriction.\n4. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score: 0-2.\n5. Life expectancy was estimated to be at least 3 months.\n6. No previous anti-tumor treatment specifically for SCLC was administered.\n7. According to the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, there must be at least one measurable lesion.\n8. Patients' organ functions must be adequately sufficient, with the following requirements to be met before the first study treatment:\n\n   1. Hematological parameters: ANC ≥1.5×10\\^9\u002FL, platelets ≥100×10\\^9\u002FL, hemoglobin ≥90g\u002FL.\n   2. Renal function: serum creatinine ≤1.5 times the upper limit, or creatinine clearance ≥50 mL\u002Fmin.\n   3. Liver function: ALT\u002FAST ≤2.5 times the upper limit, total serum bilirubin ≤2 times the upper limit.\n   4. Coagulation: INR should be ≤ 1.5 times the upper limit.\n9. Patients of childbearing potential must agree to use contraception.\n10. Patients must be able to tolerate chemotherapy, immunotherapy, and surgery.\n\nExclusion Criteria:\n\n1. Patients who have received anti-tumor treatment for SCLC (including but not limited to chemotherapy and radiation therapy at the site of the lesion).\n2. Patients who have previously used immune checkpoint inhibitors such as PD-1\u002FPD-L1 inhibitors for treatment.\n3. Patients with a history of interstitial lung disease, non-infectious pneumonia, or uncontrollable systemic diseases, including pulmonary fibrosis and acute lung disease.\n4. Patients requiring systemic anti-bacterial, anti-fungal, or anti-viral treatment for severe chronic or active infections, including tuberculosis.\n5. Patients known to have HIV.\n6. Patients with active hepatitis B or hepatitis C.\n7. Patients with active autoimmune diseases or a history of autoimmune diseases that may recur.\n8. Patients with diseases requiring systemic corticosteroid treatment or other immunosuppressive therapy.\n9. Patients deemed by the investigator to have concomitant diseases that pose a serious risk to patient safety or could affect the patient's ability to complete the study.\n10. Patients who have undergone major surgery within 4 weeks prior to treatment initiation, or those with significant trauma or fractures, or those with unhealed wounds at the time of treatment.\n11. Patients with severe cardiac diseases, such as NYHA class III or higher congestive heart failure, CCS class III or higher angina, a history of myocardial infarction in the past 6 months, or arrhythmias requiring medication.\n12. Patients with comorbidities that make them unsuitable for surgery.\n13. Patients who have had an allergic reaction to the study drug or excipients in the medication.",{"count":73,"type":22},60,[52],"This is an open-label, non-randomized, controlled, single-center, phase II study to compare the efficacy and safety of neoadjuvant PD-L1\u002FPD-1 inhibitor + chemotherapy (carboplatin\u002Fcisplatin + etoposide) with chemotherapy (carboplatin\u002Fcisplatin + etoposide) alone followed by radical surgery and adjuvant treatment as perioperative therapy in patients with limited-stage SCLC.",[77],"Limited-stage Small-cell Lung Cancer","NOT_YET_RECRUITING","2024-04-17",{"date":81,"type":31},"2024-04-19",{"date":83,"type":22},"2024-04-16",{"date":85,"type":22},"2029-04-15",{"name":37,"class":38},""]